{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:29:07Z","timestamp":1740144547447,"version":"3.37.3"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005366","name":"University of Oslo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Prader-Willi syndrome (PWS) is a rare genetic neurodevelopmental syndrome with highly increased risk of obesity and cardiovascular disease (CVD). Recent evidence suggests that inflammation is implicated in the pathogenesis. Here we investigated CVD related immune markers to shed light on pathogenetic mechanisms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a cross-sectional study with 22 participants with PWS and 22 healthy controls (HC), and compared levels of 21 inflammatory markers that reflect activity in different aspects of CVD related immune pathways and analyzed their association with clinical CVD risk factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Serum levels of matrix metalloproteinase 9 (MMP-9) was (median (range)) 121 (182) ng\/ml in PWS versus 44 (51) ng\/ml in HC, p\u2009=\u20091\u2009\u00d7\u200910<jats:sup>-9<\/jats:sup>), myeloperoxidase (MPO) was 183 (696) ng\/ml versus 65 (180) ng\/ml, p\u2009=\u20091\u2009\u00d7\u200910<jats:sup>-5<\/jats:sup>) and macrophage inhibitory factor (MIF) was 46 (150) ng\/ml versus 121 (163) ng\/ml (p\u2009=\u20091\u2009\u00d7\u200910<jats:sup>-3<\/jats:sup>), after adjusting for age and sex. Also other markers tended to be elevated (OPG, sIL2RA, CHI3L1, VEGF) but not significantly after Bonferroni correction (p\u2009&gt;\u20090.002). As expected PWS had higher body mass index, waist circumference, leptin, C-reactive protein, glycosylated hemoglobin (HbA1c), VAI and cholesterol, but MMP-9, MPO and MIF remained significantly different in PWS after adjustment for these clinical CVD risk factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>PWS had elevated levels of MMP-9 and MPO and of reduced levels of MIF, which were not secondary to comorbid CVD risk factors. This immune profile suggests enhanced monocyte\/neutrophil activation, impaired macrophage inhibition with enhanced extracellular matrix remodeling. These findings warrant further studies targeting these immune pathways in PWS.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-023-02730-5","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T11:01:54Z","timestamp":1688986914000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Systemic immune profile in Prader-Willi syndrome: elevated matrix metalloproteinase and myeloperoxidase and reduced macrophage inhibitory factor"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0115-5285","authenticated-orcid":false,"given":"Sigrun","family":"Hope","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terje","family":"N\u00e6rland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svein","family":"Olav Kolset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thor","family":"Ueland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole A.","family":"Andreassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Nordstr\u00f8m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,10]]},"reference":[{"issue":"1","key":"2730_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/gim.0b013e31822bead0","volume":"14","author":"SB Cassidy","year":"2012","unstructured":"Cassidy SB, et al. Prader-Willi syndrome. Genet Med. 2012;14(1):10\u201326.","journal-title":"Genet Med"},{"issue":"3","key":"2730_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1136\/adc.88.3.263","volume":"88","author":"A Smith","year":"2003","unstructured":"Smith A, et al. Birth prevalence of Prader-Willi syndrome in Australia. Arch Dis Child. 2003;88(3):263\u20134.","journal-title":"Arch Dis Child"},{"issue":"12","key":"2730_CR3","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s40618-015-0312-9","volume":"38","author":"MA Angulo","year":"2015","unstructured":"Angulo MA, Butler MG, Cataletto ME. Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings. J Endocrinol Invest. 2015;38(12):1249\u201363.","journal-title":"J Endocrinol Invest"},{"issue":"11","key":"2730_CR4","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.1210\/jc.2008-0649","volume":"93","author":"AP Goldstone","year":"2008","unstructured":"Goldstone AP, et al. Recommendations for the diagnosis and management of Prader-Willi syndrome. J Clin Endocrinol Metab. 2008;93(11):4183\u201397.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2730_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3109\/13668250.2016.1167845","volume":"41","author":"M Nordstrom","year":"2016","unstructured":"Nordstrom M, et al. The prevalence of metabolic risk factors of atherosclerotic cardiovascular disease in Williams syndrome, Prader-Willi syndrome, and Down syndrome. J Intellect Dev Dis. 2016;41(3):187\u201396.","journal-title":"J Intellect Dev Dis"},{"issue":"11","key":"2730_CR6","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.numecd.2012.11.006","volume":"23","author":"G Grugni","year":"2013","unstructured":"Grugni G, et al. Metabolic syndrome in adult patients with Prader-Willi syndrome. Nutr Metab Cardiovasc Dis. 2013;23(11):1134\u201340.","journal-title":"Nutr Metab Cardiovasc Dis"},{"doi-asserted-by":"crossref","unstructured":"Butler MG, Oyetunji A, Manzardo AM. Age distribution, Comorbidities and Risk factors for thrombosis in Prader-Willi Syndrome. Genes (Basel), 2020. 11(1).","key":"2730_CR7","DOI":"10.3390\/genes11010067"},{"issue":"1","key":"2730_CR8","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s13023-019-1214-2","volume":"14","author":"DL Pacoricona Alfaro","year":"2019","unstructured":"Pacoricona Alfaro DL, et al. Causes of death in Prader-Willi syndrome: lessons from 11 years\u2019 experience of a national reference center. Orphanet J Rare Dis. 2019;14(1):238.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"2730_CR9","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/gim.2016.178","volume":"19","author":"MG Butler","year":"2017","unstructured":"Butler MG, et al. Causes of death in Prader-Willi syndrome: Prader-Willi Syndrome Association (USA) 40-year mortality survey. Genet Med. 2017;19(6):635\u201342.","journal-title":"Genet Med"},{"key":"2730_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1741-7015-11-117","volume":"11","author":"J Frosteg\u00e5rd","year":"2013","unstructured":"Frosteg\u00e5rd J. Immunity, atherosclerosis and cardiovascular disease. BMC Med. 2013;11:117.","journal-title":"BMC Med"},{"issue":"6","key":"2730_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.medcli.2020.04.024","volume":"155","author":"J Pedro-Botet","year":"2020","unstructured":"Pedro-Botet J, Climent E, Benaiges D. Atherosclerosis and inflammation. New therapeutic approaches. Med Clin (Barc). 2020;155(6):256\u201362.","journal-title":"Med Clin (Barc)"},{"issue":"21","key":"2730_CR12","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1093\/hmg\/ddx311","volume":"26","author":"TM Wijesuriya","year":"2017","unstructured":"Wijesuriya TM, et al. The Prader-Willi syndrome proteins MAGEL2 and necdin regulate leptin receptor cell surface abundance through ubiquitination pathways. Hum Mol Genet. 2017;26(21):4215\u201330.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"2730_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/(SICI)1096-8628(19980106)75:1<7::AID-AJMG3>3.0.CO;2-T","volume":"75","author":"MG Butler","year":"1998","unstructured":"Butler MG, et al. Comparison of leptin protein levels in Prader-Willi syndrome and control individuals. Am J Med Genet. 1998;75(1):7\u201312.","journal-title":"Am J Med Genet"},{"issue":"2","key":"2730_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/BF03345585","volume":"31","author":"A Caixas","year":"2008","unstructured":"Caixas A, et al. Adult subjects with Prader-Willi syndrome show more low-grade systemic inflammation than matched obese subjects. J Endocrinol Invest. 2008;31(2):169\u201375.","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"2730_CR15","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/ajmg.a.36908","volume":"167A","author":"MG Butler","year":"2015","unstructured":"Butler MG, et al. Increased plasma chemokine levels in children with Prader-Willi syndrome. Am J Med Genet A. 2015;167A(3):563\u201371.","journal-title":"Am J Med Genet A"},{"doi-asserted-by":"crossref","unstructured":"Tan Q et al. Prader\u2013Willi-Like phenotype caused by an atypical 15q11.2 Microdeletion. 2020. 11(2): p. 128.","key":"2730_CR16","DOI":"10.3390\/genes11020128"},{"issue":"12","key":"2730_CR17","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1093\/hmg\/ddab103","volume":"30","author":"MA Kocher","year":"2021","unstructured":"Kocher MA, et al. Snord116 post-transcriptionally increases Nhlh2 mRNA Stability: implications for human Prader-Willi Syndrome. Hum Mol Genet. 2021;30(12):1101\u201310.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"2730_CR18","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1210\/jc.2014-3127","volume":"100","author":"D Lacroix","year":"2015","unstructured":"Lacroix D, et al. Metabolic and adipose tissue signatures in adults with Prader-Willi syndrome: a model of extreme adiposity. J Clin Endocrinol Metab. 2015;100(3):850\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2730_CR19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1101\/gr.175919.114","volume":"25","author":"H Al Adhami","year":"2015","unstructured":"Al Adhami H, et al. A systems-level approach to parental genomic imprinting: the imprinted gene network includes extracellular matrix genes and regulates cell cycle exit and differentiation. Genome Res. 2015;25(3):353\u201367.","journal-title":"Genome Res"},{"issue":"2","key":"2730_CR20","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1542\/peds.91.2.398","volume":"91","author":"VA Holm","year":"1993","unstructured":"Holm VA, et al. Prader-Willi syndrome: consensus diagnostic criteria. Pediatrics. 1993;91(2):398\u2013402.","journal-title":"Pediatrics"},{"issue":"5","key":"2730_CR21","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1161\/01.CIR.0000154900.76284.F6","volume":"111","author":"TG Pickering","year":"2005","unstructured":"Pickering TG, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on high blood pressure research. Circulation. 2005;111(5):697\u2013716.","journal-title":"Circulation"},{"issue":"1","key":"2730_CR22","first-page":"27","volume":"66","author":"C Hoybye","year":"2006","unstructured":"Hoybye C. Inflammatory markers in adults with Prader-Willi syndrome before and during 12 months growth hormone treatment. Horm Res. 2006;66(1):27\u201332.","journal-title":"Horm Res"},{"issue":"7","key":"2730_CR23","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1210\/jc.2009-2492","volume":"95","author":"A Viardot","year":"2010","unstructured":"Viardot A, et al. Prader-Willi syndrome is associated with activation of the innate immune system independently of central adiposity and insulin resistance. J Clin Endocrinol Metab. 2010;95(7):3392\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2730_CR24","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s11033-018-4279-4","volume":"45","author":"M Ali","year":"2018","unstructured":"Ali M, et al. Neutrophil elastase and myeloperoxidase mRNA expression in overweight and obese subjects. Mol Biol Rep. 2018;45(5):1245\u201352.","journal-title":"Mol Biol Rep"},{"issue":"11","key":"2730_CR25","doi-asserted-by":"publisher","first-page":"8283","DOI":"10.1002\/jcp.29485","volume":"235","author":"C Wang","year":"2020","unstructured":"Wang C, et al. MMP9, CXCR1, TLR6, and MPO participant in the progression of coronary artery disease. J Cell Physiol. 2020;235(11):8283\u201392.","journal-title":"J Cell Physiol"},{"issue":"6","key":"2730_CR26","doi-asserted-by":"publisher","first-page":"H2500","DOI":"10.1152\/ajpheart.00432.2003","volume":"285","author":"LB Garner","year":"2003","unstructured":"Garner LB, et al. Macrophage migration inhibitory factor is a cardiac-derived myocardial depressant factor. Am J Physiol Heart Circ Physiol. 2003;285(6):H2500\u20139.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"2730_CR27","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/biof.1711","volume":"47","author":"L Gligorovska","year":"2021","unstructured":"Gligorovska L, et al. Macrophage migration inhibitory factor deficiency aggravates effects of fructose-enriched diet on lipid metabolism in the mouse liver. BioFactors. 2021;47(3):363\u201375.","journal-title":"BioFactors"},{"issue":"3","key":"2730_CR28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1161\/CIRCULATIONAHA.112.000862","volume":"128","author":"J Wang","year":"2013","unstructured":"Wang J, et al. Limiting cardiac ischemic injury by pharmacological augmentation of macrophage migration inhibitory factor-AMP-activated protein kinase signal transduction. Circulation. 2013;128(3):225\u201336.","journal-title":"Circulation"},{"key":"2730_CR29","doi-asserted-by":"publisher","first-page":"22488","DOI":"10.1038\/srep22488","volume":"6","author":"X Xu","year":"2016","unstructured":"Xu X, et al. Macrophage Migration Inhibitory factor (MIF) Deficiency exacerbates Aging-Induced Cardiac Remodeling and Dysfunction despite Improved inflammation: role of Autophagy Regulation. Sci Rep. 2016;6:22488.","journal-title":"Sci Rep"},{"issue":"10","key":"2730_CR30","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.1096\/fj.14-253625","volume":"28","author":"S Zhang","year":"2014","unstructured":"Zhang S, et al. Down-regulation of MIF by NF\u03baB under hypoxia accelerated neuronal loss during stroke. Faseb j. 2014;28(10):4394\u2013407.","journal-title":"Faseb j"},{"issue":"2","key":"2730_CR31","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.gene.2015.07.023","volume":"572","author":"M Falaleeva","year":"2015","unstructured":"Falaleeva M, et al. SNORD116 and SNORD115 change expression of multiple genes and modify each other\u2019s activity. Gene. 2015;572(2):266\u201373.","journal-title":"Gene"},{"key":"2730_CR32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.molimm.2020.01.021","volume":"120","author":"J Hamelin-Morrissette","year":"2020","unstructured":"Hamelin-Morrissette J, et al. Leukemia inhibitory factor regulates the activation of inflammatory signals in macrophages and trophoblast cells. Mol Immunol. 2020;120:32\u201342.","journal-title":"Mol Immunol"},{"issue":"2","key":"2730_CR33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nm0202-157","volume":"8","author":"B Homey","year":"2002","unstructured":"Homey B, et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med. 2002;8(2):157\u201365.","journal-title":"Nat Med"},{"doi-asserted-by":"crossref","unstructured":"Chen L, Zhu L, Chen J. Human Interferon Inducible Transmembrane Protein 3 (IFITM3) Inhibits Influenza Virus A Replication and Inflammation by Interacting with ABHD16A Biomed Res Int, 2021. 2021: p.\u00a06652147.","key":"2730_CR34","DOI":"10.1155\/2021\/6652147"},{"key":"2730_CR35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.abb.2018.01.004","volume":"640","author":"Y Aratani","year":"2018","unstructured":"Aratani Y. Myeloperoxidase: its role for host defense, inflammation, and neutrophil function. Arch Biochem Biophys. 2018;640:47\u201352.","journal-title":"Arch Biochem Biophys"},{"doi-asserted-by":"crossref","unstructured":"Qorri B et al. Agonist-biased signaling via Matrix Metalloproteinase-9 promotes Extracellular Matrix Remodeling. Cells, 2018. 7(9).","key":"2730_CR36","DOI":"10.3390\/cells7090117"},{"issue":"1","key":"2730_CR37","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41598-019-57299-6","volume":"10","author":"H Cai","year":"2020","unstructured":"Cai H, et al. Binding of myeloperoxidase to the extracellular matrix of smooth muscle cells and subsequent matrix modification. Sci Rep. 2020;10(1):666.","journal-title":"Sci Rep"},{"issue":"2","key":"2730_CR38","first-page":"3425","volume":"17","author":"YM Xue","year":"2018","unstructured":"Xue YM, et al. Macrophage migration inhibitory factor promotes cardiac fibroblast proliferation through the src kinase signaling pathway. Mol Med Rep. 2018;17(2):3425\u201331.","journal-title":"Mol Med Rep"},{"key":"2730_CR39","doi-asserted-by":"publisher","first-page":"116927","DOI":"10.1016\/j.lfs.2019.116927","volume":"254","author":"X Li","year":"2020","unstructured":"Li X, et al. Targeted depletion of monocyte\/macrophage suppresses aortic dissection with the spatial regulation of MMP-9 in the aorta. Life Sci. 2020;254:116927.","journal-title":"Life Sci"},{"issue":"6","key":"2730_CR40","first-page":"391","volume":"28","author":"A Yabluchanskiy","year":"2013","unstructured":"Yabluchanskiy A, et al. Matrix metalloproteinase-9: many shades of function in cardiovascular disease. Physiol (Bethesda). 2013;28(6):391\u2013403.","journal-title":"Physiol (Bethesda)"},{"doi-asserted-by":"crossref","unstructured":"Heinecke JW, Goldberg IJ. Myeloperoxidase: a therapeutic target for preventing insulin resistance and the metabolic sequelae of obesity? 2014. 63(12): p. 4001\u20133.","key":"2730_CR41","DOI":"10.2337\/db14-1273"},{"issue":"6","key":"2730_CR42","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3109\/00365510902912747","volume":"69","author":"A Gummesson","year":"2009","unstructured":"Gummesson A, et al. Adipose tissue is not an important source for matrix metalloproteinase-9 in the circulation. Scand J Clin Lab Invest. 2009;69(6):636\u201342.","journal-title":"Scand J Clin Lab Invest"},{"issue":"5","key":"2730_CR43","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/ajmg.a.31677","volume":"146A","author":"JL Miller","year":"2008","unstructured":"Miller JL, et al. Pituitary abnormalities in Prader-Willi syndrome and early onset morbid obesity. Am J Med Genet A. 2008;146A(5):570\u20137.","journal-title":"Am J Med Genet A"},{"issue":"14","key":"2730_CR44","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1096\/fasebj.10.14.9002552","volume":"10","author":"R Bucala","year":"1996","unstructured":"Bucala R. MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid-induced regulator of the immune response. FASEB J. 1996;10(14):1607\u201313.","journal-title":"FASEB J"},{"issue":"3","key":"2730_CR45","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s12020-018-1666-5","volume":"62","author":"G Grugni","year":"2018","unstructured":"Grugni G, et al. Autoimmune pituitary involvement in Prader-Willi syndrome: new perspective for further research. Endocrine. 2018;62(3):733\u20136.","journal-title":"Endocrine"},{"issue":"8","key":"2730_CR46","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/13543776.2020.1780210","volume":"30","author":"J Soubhye","year":"2020","unstructured":"Soubhye J, Van Antwerpen P, Dufrasne F. A patent review of myeloperoxidase inhibitors for treating chronic inflammatory syndromes (focus on cardiovascular diseases, 2013\u20132019). Expert Opin Ther Pat. 2020;30(8):595\u2013608.","journal-title":"Expert Opin Ther Pat"},{"issue":"6","key":"2730_CR47","doi-asserted-by":"publisher","first-page":"H1414","DOI":"10.1152\/ajpheart.00032.2020","volume":"319","author":"SS Nandi","year":"2020","unstructured":"Nandi SS, et al. MMP9 inhibition increases autophagic flux in chronic heart failure. Am J Physiol Heart Circ Physiol. 2020;319(6):H1414\u201337.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"9","key":"2730_CR48","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1007\/s11064-017-2265-1","volume":"42","author":"W Walz","year":"2017","unstructured":"Walz W, Cayabyab FS. Neutrophil infiltration and Matrix Metalloproteinase-9 in Lacunar Infarction. Neurochem Res. 2017;42(9):2560\u20135.","journal-title":"Neurochem Res"},{"issue":"6","key":"2730_CR49","doi-asserted-by":"publisher","first-page":"e0217437","DOI":"10.1371\/journal.pone.0217437","volume":"14","author":"HW Wang","year":"2019","unstructured":"Wang HW, et al. Inhibition of inflammation by minocycline improves heart failure and depression-like behaviour in rats after myocardial infarction. PLoS ONE. 2019;14(6):e0217437.","journal-title":"PLoS ONE"},{"key":"2730_CR50","doi-asserted-by":"publisher","first-page":"112068","DOI":"10.1016\/j.bbr.2019.112068","volume":"372","author":"MA Toledo","year":"2019","unstructured":"Toledo MA, et al. Reversal of ultrasonic vocalization deficits in a mouse model of Fragile X syndrome with minocycline treatment or genetic reduction of MMP-9. Behav Brain Res. 2019;372:112068.","journal-title":"Behav Brain Res"},{"issue":"8","key":"2730_CR51","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1002\/ajmg.a.36023","volume":"161A","author":"M Dziembowska","year":"2013","unstructured":"Dziembowska M, et al. High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. Am J Med Genet A. 2013;161A(8):1897\u2013903.","journal-title":"Am J Med Genet A"},{"key":"2730_CR52","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.neuint.2017.05.020","volume":"111","author":"J Zhang","year":"2017","unstructured":"Zhang J, et al. Inhibition of na(+)-K(+)-2Cl(-) cotransporter attenuates blood-brain-barrier disruption in a mouse model of traumatic brain injury. Neurochem Int. 2017;111:23\u201331.","journal-title":"Neurochem Int"},{"issue":"1","key":"2730_CR53","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13229-020-00335-4","volume":"11","author":"DM van Andel","year":"2020","unstructured":"van Andel DM, et al. Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study. Mol Autism. 2020;11(1):30.","journal-title":"Mol Autism"},{"key":"2730_CR54","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.brainres.2012.03.009","volume":"1453","author":"S Li","year":"2012","unstructured":"Li S, et al. Increased expression of matrix metalloproteinase 9 in cortical lesions from patients with focal cortical dysplasia type IIb and tuberous sclerosis complex. Brain Res. 2012;1453:46\u201355.","journal-title":"Brain Res"},{"issue":"3","key":"2730_CR55","doi-asserted-by":"publisher","first-page":"e0120737","DOI":"10.1371\/journal.pone.0120737","volume":"10","author":"F Shaeib","year":"2015","unstructured":"Shaeib F, et al. Melatonin prevents myeloperoxidase heme destruction and the generation of free iron mediated by self-generated hypochlorous acid. PLoS ONE. 2015;10(3):e0120737.","journal-title":"PLoS ONE"},{"doi-asserted-by":"crossref","unstructured":"Dominguez-Rodriguez A et al. Early Treatment of Acute Myocardial Infarction with Melatonin: Effects on MMP-9 and Adverse Cardiac Events J Clin Med, 2022. 11(7).","key":"2730_CR56","DOI":"10.3390\/jcm11071909"},{"issue":"suppl 64","key":"2730_CR57","first-page":"2904","volume":"56","author":"Z Nie","year":"2020","unstructured":"Nie Z, Jacoby D, Fryer A. Pioglitazone inhibits obesity-related airway hyperreactivity. 2020;56(suppl 64):2904.","journal-title":"Pioglitazone inhibits obesity-related airway hyperreactivity"},{"issue":"8","key":"2730_CR58","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/1753-0407.12894","volume":"11","author":"S Miao","year":"2019","unstructured":"Miao S, et al. Detecting pioglitazone use and risk of cardiovascular events using electronic health record data in a large cohort of chinese patients with type 2 diabetes. J Diabetes. 2019;11(8):684\u20139.","journal-title":"J Diabetes"},{"issue":"6","key":"2730_CR59","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/BF03402125","volume":"5","author":"S Sakaue","year":"1999","unstructured":"Sakaue S, et al. Regulation of macrophage migration inhibitory factor (MIF) expression by glucose and insulin in adipocytes in vitro. Mol Med. 1999;5(6):361\u201371.","journal-title":"Mol Med"},{"doi-asserted-by":"crossref","unstructured":"Mahmoud R, Kimonis V, Butler MG. Clinical trials in Prader-Willi Syndrome: a review. Int J Mol Sci, 2023. 24(3).","key":"2730_CR60","DOI":"10.3390\/ijms24032150"},{"issue":"6","key":"2730_CR61","first-page":"337","volume":"24","author":"S Momenabadi","year":"2022","unstructured":"Momenabadi S, et al. Pre-ischemic oxytocin treatment alleviated neuronal Injury via suppressing NF-\u03baB, MMP-9, and apoptosis Regulator Proteins in a mice Model of Stroke. Cell J. 2022;24(6):337\u201345.","journal-title":"Cell J"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02730-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02730-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02730-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T12:11:44Z","timestamp":1688991104000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02730-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,10]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2730"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02730-5","relation":{},"ISSN":["1750-1172"],"issn-type":[{"type":"electronic","value":"1750-1172"}],"subject":[],"published":{"date-parts":[[2023,7,10]]},"assertion":[{"value":"14 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided an informed consent to participate together with consent from legal guardian\/parent. The study was approved by the Regional Committee for Medical and Health Research Ethics, Southeast Region approved the study (#2012\/140). The study was also approved by Data Protection Officer at Norwegian Centre for Reseach Data (# 786243).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Ole A. Andreassen is a consultant to HealthLytix, and received speaker\u2019s honorarium from Lundbeck and Sunovion. Other authors report no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"185"}}